Show simple item record

Innate and cellular immune response to the Ebola vaccine Ad26.ZEBOV, MVA-BN-Filo: an ancillary study of the EBL2001 phase II trial

dc.rights.licenseopenen_US
dc.contributor.authorLACABARATZ, Christine
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDURAND, Melany
dc.contributor.authorWIEDEMANN, Aurelie
dc.contributor.authorFOUCAT, Emile
dc.contributor.authorSURENAUD, Mathieu
dc.contributor.authorKRIEF, Corinne
dc.contributor.authorGUILLAUMAT, Lydia
dc.contributor.authorROBINSON, Cynthia
dc.contributor.authorLUHN, Kerstin
dc.contributor.authorBOCKSTAL, Viki
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTHIEBAUT, Rodolphe
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorRICHERT, Laura
dc.contributor.authorLEVY, Yves
dc.date.accessioned2024-10-14T08:29:05Z
dc.date.available2024-10-14T08:29:05Z
dc.date.issued2024-07-16
dc.identifier.issn1537-6613en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/202465
dc.description.abstractEnBACKGROUND: The EBL2001 phase 2 trial tested the two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine in Europe. Safety and humoral immunogenicity assessments led to EU market authorization in 2020. Complementary analyses of immune responses are warranted to better characterize vaccine effects. METHODS: We conducted an ancillary study to analyze changes in the serum and cellular responses. Serum biomarkers of activation/inflammation were evaluated using a Luminex assay. Vaccine-elicited T cell responses and functions were evaluated assessing their phenotype, cytokine production, proliferation and cytotoxic potential. Integrated data analysis was performed through correlation and principal component analysis of serum biomarkers and cellular immune responses. RESULTS: Forty-eight volunteers were included. The Ad26.ZEBOV, MVA-BN-Filo vaccine elicited: i) serum increase of inflammatory/activation markers mainly at 1 day after the Ad26.ZEBOV vaccine; ii) durable EBOV-specific T cell proliferation and CD8+ T cells exhibiting a cytotoxic phenotype after Ad26.ZEBOV prime, after MVA-BN-Filo boost and 6 months post vaccination. Integrated analysis revealed correlations between: i) EBOV-specific CD8+ T cell proliferation and cytotoxic phenotype; ii) high EBOV-specific CD8+ T cell cytotoxic phenotype and low inflammatory marker IL-8 at day 1 post vaccination. DISCUSSION: This study provides unique insights into the in vivo contribution of proliferation/cytotoxic CD8+ T cells and inflammation to the Ad26.ZEBOV, MVA-BN-Filo vaccine-induced potency.
dc.description.sponsorshipInitiative for the creation of a Vaccine Research Institute - ANR-10-LABX-0077en_US
dc.language.isoENen_US
dc.subject.enEbola
dc.subject.enVaccine immunogenicity
dc.subject.enT-cell responses
dc.subject.enBiomarkers
dc.subject.enAntibody
dc.title.enInnate and cellular immune response to the Ebola vaccine Ad26.ZEBOV, MVA-BN-Filo: an ancillary study of the EBL2001 phase II trial
dc.title.alternativeJ Infect Disen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/infdis/jiae360en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed39012798en_US
bordeaux.journalJournal of Infectious Diseasesen_US
bordeaux.pagejiae360en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionINRIAen_US
bordeaux.teamSISTM_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDHorizon 2020en_US
hal.identifierhal-04734724
hal.version1
hal.date.transferred2024-10-14T08:29:08Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Infectious%20Diseases&rft.date=2024-07-16&rft.spage=jiae360&rft.epage=jiae360&rft.eissn=1537-6613&rft.issn=1537-6613&rft.au=LACABARATZ,%20Christine&DURAND,%20Melany&WIEDEMANN,%20Aurelie&FOUCAT,%20Emile&SURENAUD,%20Mathieu&rft.genre=article


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record